Our study aligns with other reports that demonstrated reduced or unchanged levels of hepatic IL-22 expression in males, including humans and mice, with MASLD compared to healthy controls (232, 233, 278). This evidence concerns the gene IL22 and metabolic dysfunction-associated steatotic liver disease.